Avalo Therapeutics, Inc. (AVTX) stock
AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.37−0.39 (-5.03%)
Close on Nov 16, 2026Market cap $395.25MP/E –Yield –
Avalo Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Avalo Therapeutics's operating margin for the twelve months ending Dec 31, 2025 was -123601.7%. For fiscal 2025 it was -123601.7%, against -15535.6% the year before. The highest annual figure on record is 49.9% in fiscal 2017.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -123601.7% | −108066.1 |
| FY2024 | Dec 31, 2024 | -15535.6% | −14114.0 |
| FY2023 | Dec 31, 2023 | -1421.6% | −1214.2 |
| FY2022 | Dec 31, 2022 | -207.4% | +1314.2 |
| FY2021 | Dec 31, 2021 | -1521.6% | −434.2 |
| FY2020 | Dec 31, 2020 | -1087.4% | −848.3 |
| FY2019 | Dec 31, 2019 | -239.1% | +264.3 |
| FY2018 | Dec 31, 2018 | -503.4% | −553.3 |
| FY2017 | Dec 31, 2017 | 49.9% | +1444.6 |
| FY2016 | Dec 31, 2016 | -1394.6% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -33461.0% | −31872.0 |
| Q4 FY2024 | Dec 31, 2024 | -6932.8% | −5820.8 |
| Q3 FY2024 | Sep 30, 2024 | -5165.1% | −3314.1 |
| Q4 FY2023 | Dec 31, 2023 | -1341.2% | −352.9 |
| Q3 FY2023 | Sep 30, 2023 | -1589.0% | −1616.4 |
| Q2 FY2023 | Jun 30, 2023 | -1112.0% | +33.0 |
| Q1 FY2023 | Mar 31, 2023 | -1850.9% | −73.2 |
| Q4 FY2022 | Dec 31, 2022 | -988.3% | +7214.0 |
| Q3 FY2022 | Sep 30, 2022 | 27.4% | +1246.9 |
| Q2 FY2022 | Jun 30, 2022 | -1145.0% | −634.5 |
| Q1 FY2022 | Mar 31, 2022 | -1777.7% | +4687.4 |
| Q4 FY2021 | Dec 31, 2021 | -8202.3% | −7110.8 |
| Q3 FY2021 | Sep 30, 2021 | -1219.5% | −24.4 |
| Q2 FY2021 | Jun 30, 2021 | -510.6% | +372.5 |
| Q1 FY2021 | Mar 31, 2021 | -6465.1% | −5324.5 |
| Q4 FY2020 | Dec 31, 2020 | -1091.4% | −106.1 |
| Q3 FY2020 | Sep 30, 2020 | -1195.0% | −1065.1 |
| Q2 FY2020 | Jun 30, 2020 | -883.0% | −700.0 |
| Q1 FY2020 | Mar 31, 2020 | -1140.6% | −946.4 |
| Q4 FY2019 | Dec 31, 2019 | -985.3% | −954.1 |
| Q3 FY2019 | Sep 30, 2019 | -130.0% | +466.7 |
| Q2 FY2019 | Jun 30, 2019 | -183.1% | −62.8 |
| Q1 FY2019 | Mar 31, 2019 | -194.3% | −110.5 |
| Q4 FY2018 | Dec 31, 2018 | -31.3% | +196.7 |
| Q3 FY2018 | Sep 30, 2018 | -596.7% | −684.2 |
| Q2 FY2018 | Jun 30, 2018 | -120.2% | +1004.6 |
| Q1 FY2018 | Mar 31, 2018 | -83.8% | +410.5 |
| Q4 FY2017 | Dec 31, 2017 | -228.0% | +703.7 |
| Q3 FY2017 | Sep 30, 2017 | 87.6% | +1942.4 |
| Q2 FY2017 | Jun 30, 2017 | -1124.8% | – |
| Q1 FY2017 | Mar 31, 2017 | -494.3% | – |
| Q4 FY2016 | Dec 31, 2016 | -931.7% | – |
| Q3 FY2016 | Sep 30, 2016 | -1854.9% | – |
See a number that looks wrong?